Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | WDR5 | P61964 | 5/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017976 | 0.85 | CXCR4 (0.61) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL6019482 | 0.80 | CXCR4 (0.50) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL6677936 | 0.77 | CXCR4 (0.53) | CXCR4F2WDR5ITGB3ITGAV | |
| SCHEMBL6655088 | 0.76 | CXCR4 (0.68) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL6677932 | 0.75 | CXCR4 (0.49) | CXCR4FNTAFNTBPGGT1BF2 | |
| SCHEMBL6656132 | 0.75 | CXCR4 (0.51) | CXCR4F2WDR5ITGB3ITGAV | |
| SCHEMBL6018824 | 0.75 | CXCR4 (0.47) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL6018092 | 0.75 | CXCR4 (0.47) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL6653556 | 0.74 | CXCR4 (0.42) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL7022515 | 0.74 | CXCR4 (0.53) | CXCR4FNTAFNTBPGGT1BF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | NGLY1, NOD1, CCR1 | CXCR4 88/4885FNTA 2530/4885FNTB 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.